MAIN OUTCOME MEASURES The primary outcome was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected nasal swabs over the winter months. Secondary outcomes included the number of influenza infections, noninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin D levels at study termination.
V iral upper respiratory tract infections are the most common infectious illnesses of childhood. 1 From the mid1980s and onward, vitamin D has received attention for its potential to prevent disease through its role in both innate and adaptive immune responses. 2 Both observational and clinical trial data have suggested a link between low levels of serum 25-hydroxyvitamin D and increased rates of respiratory tract infections. 3, 4 In addition to the morbidity they cause, upper respiratory tract infections place a considerable economic burden on health care systems and societies. 5 Vitamin D increases the synthesis of the antimicrobial peptide cathelicidin in respiratory epithelium, 6 which has been shown to reduce disease severity and replication of the influenza virus in vitro. 7 Although a number of clinical trials have attempted to assess the effect of vitamin D supplementation on the prevention of respiratory tract infections among adults [8] [9] [10] [11] and children, 12, 13 conclusions have been hampered by small sample sizes, short trial duration, and lack of laboratory-confirmed outcomes. Likewise, a metaanalysis of 7 clinical trials found no association between vitamin D and childhood acute respiratory infections, but limitations included a shortage of studies and heterogeneity in terms of populations and end points. 14 To our knowledge, only 1 trial has assessed the effect of vitamin D on laboratory-confirmed upper respiratory tract infections in children specifically. 12 It included 334 children in Japan and found a significant reduction in influenza A, but not influenza B, among children receiving 1200 IU/d of vitamin D supplementation. 12 
Methods

Study Design and Participants
This study was a multisite pragmatic randomized clinical superiority trial conducted in Toronto, Ontario, Canada (latitude 43°north). The study was designed as a parallel group trial with a 1:1 allocation over the 2011-2015 winter seasons. No changes to methods were made after trial commencement. Ethical approval was granted by St Michael's Hospital and Hospital for Sick Children Research Ethics Boards. Written, informed consent was obtained from parents willing to participate and provide baseline measures. Trial procedures have been described in detail elsewhere (see Supplement 1) .
Eligible participants were healthy children aged 1 to 5 years. Exclusion criteria were gestational age younger than 32 weeks and chronic illness (other than asthma). The study took place at 8 pediatric or family medicine group practices participating in TARGet Kids!, a primary care research network. Each site has between 3 and 10 practicing physicians. Parents of children scheduled for a well-child visit prior to the viral season (September through November) each year between 2011 and 2015 were approached to participate in the study.
Randomization and Blinding
Children were randomized to receive 1 of 2 formulations: the standard dose, 400 IU/d of vitamin D, or the high dose, 2000 IU/d. The standard dose was chosen to be consistent with vitamin D guidelines from the American Academy of Pediatrics (AAP) 15 and high dose was chosen to be within the tolerable upper vitamin D intake specified by the Institute of Medicine. 16 Children could only be randomized into the trial during 1 winter season. Parents of participants received a drop-based formulation in order to ease administration of the study drug (Kids Ddrops containing Vitamin D 3 17 ) . From the time of enrollment (September-November) until follow-up (April-May), parents were instructed to administer 1 drop of the provided solution to their child by mouth once each day. Drops were identical in taste, volume, and color between the intervention groups; they differed only in concentration of vitamin D. Drops could be given at any time during the day. The recruitment time window was chosen with the knowledge that the circulation of respiratory viruses peaks during the winter months and serum 25-hydroxyvitamin D levels are known to stabilize within 8 weeks. 18, 19 The duration of the dosing regimen (4-8 months) was selected to follow the routine practice of supplementing preschoolers with vitamin D over the winter months.
Procedures
After providing informed consent, parents completed a standardized data collection form with questions adapted from the Canadian Community Health Survey. These included age; sex; birth weight; enrollment date; skin pigmentation; parents' race/ethnicity; maternal age, educational level, and health status; duration of breastfeeding; bottle use; current and past vitamin D supplementation; influenza immunization status; physical activity; outdoor time; and sun exposure. Skin pigmentation and ethnicity were captured in this study since previous work has suggested that both factors are related to the cutaneous production of vitamin D. 23, 24 Ethnicity was reported by the parent using fixed categories and skin pigmentation was assessed by trained research assistants through fixed categories using the Fitzpatrick scale.
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Research assistants also recorded child height and weight using standardized techniques described elsewhere.
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Baseline serum 25-hydroxyvitamin D levels were measured using the Roche ELECSYS Vitamin D total assay (Roche Diagnostics Ltd) with a functional sensitivity of 1.60 ng/mL (to convert from ng/mL to nmol/L, multiply by 2.496) (coefficient of variance, 18.5%) and an analytical specificity of 100% for 25-hydroxyvitamin D 3.
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After receiving bottles containing the assigned formulation, parents were informed that concomitant interventions such as over-the-counter multivitamins that contain vitamin D, over-the-counter vitamin D preparations, and prescription vitamin D were prohibited. Throughout the winter months, parents were asked to complete a symptom checklist 28 and collect viral nasal swabs for every upper respiratory tract infection and were reminded through monthly telephone calls. Parents were instructed on the proper technique for obtaining nasal swabs, including storing swabs in the provided transport media in the refrigerator until couriered within 24 hours to the study laboratory. Nasal swabs collected by parents have been shown to be as effective as those obtained by health professionals in detecting respiratory viruses. 29 Parents were not required to visit their child's physician to report an upper respiratory tract infection episode. In the months of April and May the following year (4-8 months after randomization), participants and their parents returned to the physician's office, at which point a follow-up data collection form was completed and follow-up 25-hydroxyvitamin D levels were measured from venous blood samples. Parents were asked to return the bottles, and the amount of vitamin D administered was calculated by measuring the amount of remaining formulation.
The primary outcome was the number of all-cause laboratory-confirmed viral upper respiratory tract infections per child. This was ascertained by detecting the presence of respiratory viruses in parent-collected nasal swabs using the Luminex xMAP ID-Tag RVP assay system (Luminex Corp), which tested for 18 common viruses including influenza A and B, adenoviruses, respiratory syncytial virus, picornaviruses, coronavirus, human metapneumovirus, and parainfluenza viruses with an overall clinical sensitivity that exceeds 92% for all targets and an overall specificity that exceeds 97% for all targets. 30 Defining respiratory infection using laboratory confirmation avoids the uncertainty associated with symptoms and illness presentations through parent reported measures. Secondary outcomes included time to first laboratoryconfirmed, total parent-reported, laboratory-confirmed influenza, and noninfluenza upper respiratory tract infections and serum 25-hydroxyvitamin D levels. Other secondary outcomes not presented in this article included asthma exacerbations among children with asthma, physician-diagnosed otitis media and pneumonia, emergency department visits, and hospitalizations.
Sample Size and Statistical Analysis
It was assumed that participants would have an average of 1 laboratory-confirmed upper respiratory tract infection per month during the minimum 4-month winter period.
31,32 Considering that the infections in children can be stressful and disruptive for families 33 and that studies suggest that a reduction of infectious burden between 25% and 30% is relevant to patients, 9, 34 we assumed a reduction of 1 per winter would have clinical importance. Under these assumptions, it was estimated that a sample of 300 participants per group would be required to detect this effect with 90% power at the .05 level of significance. This number was increased to 375 children per group to compensate for loss to follow-up. The sample size assumed a Poisson distributed outcome and was based on asymptotic methods for a likelihood ratio test.
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The number of upper respiratory tract infection events per child was summed and the mean infection rates (per child) per group were calculated. For the primary analysis comparing the number of laboratory-confirmed infections per group, a negative-binomial model using the variable length of follow-up as an offset was computed. An offset variable is the length of time a participant was observed. The offset was used to adjust for varying lengths of participant follow-up. The negative binomial model produces an incidence rate ratio (RR), which provides a relative measure of the effect of high-dose vs standard-dose vitamin D supplementation. It is derived as the number of incident infections per season for the 2000-IU/d group divided by the number of incident infections per season for the 400-IU/d group. Parental-reported infections were compared using a similar method. Time to first infection was examined using KaplanMeier curves and the log-rank test. Prespecified analyses of influenza and noninfluenza incidence were conducted using Poisson and negative-binomial models respectively using length of follow-up as an offset. Complete case analysis was performed for all primary and secondary outcomes in which only cases with available data were analyzed. Adverse events were monitored by educating collaborating community physicians about the signs and symptoms of vitamin D toxicity and asking them to report any adverse events to the study. In addition, serum calcium, alkaline phosphatase, and parathyroid hormone were measured at a follow-up study visit.
All analyses were conducted using the intention-to-treat principle. The α level was 2-sided with statistical significance set at P = .05. All analyses were conducted using SAS version 9.2 (SAS Institute Inc) andRv3.2.5. 
Results
Of 1397 participants screened, 703 eligible participants consented to participate and were randomly assigned to receive 1 of the 2 vitamin D formulations ( Figure 1 ). There were no clinically important differences between the enrolled and nonenrolled participants (eTable in Supplement 2). Three hundred fifty-four participants (50.4%) were allocated to receive the standard dose, and 349 participants (49.6%) were allocated to receive the high dose. Six hundred ninetynine (99.4%) participants had data available for the primary analysis; 4 (0.6%) were lost to follow-up. Fifty-five (7.9%) discontinued treatment but completed follow-up. The mean follow-up length and exposure duration was 6.2 months (95% CI, 5.1-7.2 months) for the standard-dose group and 6.3 months (95% CI, 5.8-7.4 months) for the high-dose group. All participants with primary outcome data were included in the intention-to-treat analysis (n = 699). Four hundred sixtyfive participants (66.1%) returned bottles at the end of the study. Among bottles returned, quantities of administered formula were comparable between groups: the high-dose mean formulation administered was 5.39 g (95% CI, 5.11-5.66 g); the standard dose mean was 5.01 g (95% CI, 4.72-5.29 g). The average proportion of the intended dose received was also comparable between groups: the high dose was 98% (95% CI, 93%-102%); the standard dose, 100% (95% CI, 92%-105%).
Balance was achieved on all measured baseline characteristics. Two hundred ninety-six participants (42.3%) were girls. The mean age at recruitment was 2.70 years (95% CI, 2.58-2.81 years). The mean baseline serum 25-hydroxyvitamin D level for the high-dose group was 35.9 ng/mL (SD, 12.3 ng/mL) and was 36.9 ng/mL (SD, 11.8 ng/mL) for the standard-dose group ( Table 1) .
A total of 728 laboratory-confirmed upper respiratory tract infections occurred throughout the study period. Eight hundred eighty-three swabs were submitted by 415 participants; 155 of these swabs from 130 participants tested negative for any infection ( Table 2 ). In total, 322 participants (46.0%) had no laboratory-confirmed infections. The mean number of infections per child was 1.03 (95% CI, 0.90-1.16; the median, 1; interquartile range [IQR], 0-2) for the standard-dose group and was 1.05 (95% CI, 0.91-1.19; median, 1; IQR, 0-2) for the high-dose group, for a between-group difference of 0.02 (95% CI, −0.17 to 0.21). In the negative binomial model, there was no statistically significant difference in the rate of all-cause upper respiratory tract infections between the groups (incidence RR, 0.97; 95% CI, 0.80-1.16; Table 2 ). Site-specific incidence RRs were symmetrically distributed around the overall incidence RR (eFigure in Supplement 2).
The median time to the first laboratory-confirmed upper respiratory tract infection was 3.29 months (95% CI, 2.66-4.14 months) for the standard-dose group and 3.95 months (95% CI, 3.02-5.95 months) for the high-dose group. There was no statistically significant difference in the groups with respect to time to first laboratory-confirmed infection ( Figure 2) .
Parents reported a total of 1225 respiratory tract illness episodes, with an average of 1.91 illnesses (95% CI, 1.72-2.09) per child (median, 2; IQR, 1-3) for the standard-dose group and 1.97 illnesses (95% CI, 1.78-2.16) per child (median, 2; IQR, 1-3) for the high-dose group, for a between-group difference of 0.06 (95% CI, −0.22 to 0.33) illnesses per child. There was no statistically significant difference in the incidence of parent-reported upper respiratory tract illnesses between groups (incidence RR, 1.01; 95% CI, 0.88-1.16; Table 3 ).
There was a statistically significant difference in serum 25-hydroxyvitamin D levels between the groups (P < .001) at study termination. Mean 25-hydroxyvitamin D levels were 48.7 ng/mL (95% CI, 46.9-50.5 ng/mL) in the high-dose group and 36.8 ng/mL (95% CI, 35.4-38.2 ng/mL) in the standarddose group. After adjusting for baseline 25-hydroxyvitamin D serum levels, the high-dose group demonstrated a 12.3 ng/mL (95% CI, 10.3-14.3 ng/mL) increase in serum 25-hydroxyvitamin D levels compared with the standard-dose group at study termination (Table 3) . No adverse events were reported.
The prespecified comparison of the incidence of influenza (influenza A and influenza B combined) revealed that the incidence of influenza infections in the high-dose group was reduced by 50% (incidence RR, 0.50; 95% CI, 0.28-0.89; Table 2 ). However, relative to other infection types there were few influenza infections that occurred in each group: the number of influenza infections in the high-dose group was 16 (4.4% of all infections) vs 31 (8.5% of all infections) in the standard-dose group (mean, 0.05; 95% CI, Conclusions of systematic reviews and meta-analyses of clinical trials that have assessed the association of vitamin D in children with respiratory infections have varied and were limited by the variability of dosing regimens (bolus vs daily supplementation), age ranges (preschoolers vs adults), populations (both healthy and unhealthy participants), types of respiratory tract infections (aggregating upper and lower, bacterial and viral respiratory tract infections), outcome measurement (severity, duration, number) and laboratory confirmation of respiratory tract infection. 3, 4, 14, 36, 37 Meta-analyses of trials have demonstrated both positive 3, 4 and null 14 40 The secondary finding that vitamin D may be associated with a lower risk of influenza is limited in its interpretation given the small number of influenza infections and should be Log-rank P = .23 of 1200 IU/d of vitamin D supplementation vs placebo on the incidence of seasonal influenza A and B among children aged 6 to 15 years. They found that vitamin D supplementation reduced the incidence of influenza A but not the incidence of influenza B. In the present study, although the incidence was statistically reduced in the high-dose group, the difference in the mean number of influenza infections per child between groups was minimal (0.05 infections per season in the high-dose group vs 0.09 infections per season in the standard-dose group). Investigation of vitamin D supplementation for prevention of influenza infection in populations or seasons during which influenza is epidemic would be necessary to evaluate these findings.
The study has a number of strengths including testing the currently recommended American Academy of Pediatrics 15 standard dose of vitamin D against the safe upper limit as recommended by the Institute of Medicine. 16 Also, it was a trial designed to mimic the routine practice of supplementing children with daily vitamin D in the wintertime as recommended by many practitioners and performed in households across North America. 41 Also, the use of laboratoryconfirmed upper respiratory tract infection as the primary outcome is well-defined and unbiased. Furthermore, the trial was conducted across multiple sites including both family physician and primary care pediatric physicians suggesting generalizability across primary care settings, and it was conducted over 5 winter seasons, capturing yearly variation in upper respiratory tract infection frequency. There are several limitations to this study. First, although parents are as capable as clinicians in administering nasal swabs, 29 children may have had upper respiratory tract infections without swabs being submitted. Because daily monitoring of infections was not feasible, monthly contact with each family revealed a similar null effect of vitamin D on parent-reported upper respiratory tract illnesses. Second, this study was also not able to make comparisons to a placebo group; this was prohibited by the research ethics board due to the American Academy of Pediatrics suggested dose of 400 IU/d. 16 It is possible that 400 IU/daily may have been sufficient for a protective effect against infections. Third, like other national studies of children, baseline 25-hydroxyvitamin D serum levels at the end of the summer were relatively high 42 and this could have contributed to the lack of effect of high-dose vitamin D supplementation. Vitamin D supplementation may provide greater benefit among children with lower baseline serum 25-hydroxyvitamin D levels. 8 Previous work in healthy adults has suggested that a 25-hydroxyvitamin D concentration of 30 ng/mL is sufficient to reduce the incidence of upper respiratory tract infections. 43 Fourth, the sample size calculation was powered to detect a reduction of 1 infection per season assuming 1 infection per month, but the data demonstrated that children experienced on average 1 laboratory-confirmed upper respiratory tract infection per season. Preliminary calculations using a Poisson distribution showed that fewer infections per season required even smaller sample sizes; thus, the study was powered to detect differences in the primary outcome. 44 
Conclusions
Among healthy children aged 1 to 5 years, daily administration of 2000 IU compared with 400 IU of vitamin D supplementation did not reduce overall wintertime upper respiratory tract infections. These findings do not support the routine use of high-dose vitamin D supplementation in children for the prevention of viral upper respiratory tract infections.
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We thank all of the participating families for their time and involvement in TARGet Kids! and are grateful to all practitioners who are currently involved in the TARGet Kids! practice-based research network. Methods: This study is a pragmatic, active controlled, randomized trial. Over 4 successive winters we will recruit 750 healthy children 1-5 years of age from their primary care physician's office. Participating primary care practices are part of a CIHR funded primary healthcare research network called TARGet Kids! Recruited children will be randomly assigned to 'standard dose' (400 IU/day) vs. 'high dose' (2000 IU/day) supplemental vitamin D per day by mouth for 4 months (200 children per group). These doses of vitamin D are within the Health Canada safe dosage limit for children older than 1 year. Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Respiratory viruses will be identified using RT-PCR technology Families will be contacted monthly by telephone to ascertain the number of asthma exacerbations and to remind them to collect suspected URTI samples and complete symptom checklists. Unscheduled physician visits for URTIs and asthma exacerbations will be recorded by research assistants in each primary physician practice. In April or May, a blood sample will be taken from each child to determine 25-hydroxyvitamin D serum levels using a competitive two-step chemiluminescence assay. The primary analysis will be a comparison of laboratory confirmed URTI rate (per child) between study groups using a Poisson regression model. Secondary analyses will include a comparison of vitamin D serum levels, asthma exascerbations and the frequency of RSV, adenovirus and influenza viruses between arms. Furthermore, a cost effectiveness analysis on the effect of wintertime vitamin D supplementation of preschoolers will be undertaken using the net benefit regression approach. We have developed a CIHR funded primary-care practice based research network called TARGet Kids! to conduct observational and interventional studies in preschoolers to improve child health outcomes through primary prevention. TARGet Kids! is the only child health primary care research network in Canada. In this two year multi-centre pragmatic randomized controlled trial we will leverage established TARGet Kids! infrastructure to determine whether wintertime high dose vitamin D supplementation of preschoolers improves two common and costly child health outcomes, viral URTI and asthma exacerbations.
B. Importance
Because of Canada's northern latitude, understanding vitamin D deficiency and associated health problems is of major importance to Canadian children and their parents. Observational studies have suggested that low vitamin D levels may be implicated in two of the most common health and burdensome issues during early childhood: URTI and asthma exacerbations. These two conditions place an enormous burden on Canada's health care system and economy. Viral URTI and exacerbations of asthma combined make up over 30% of all emergency department visits for children in Canada. [5] If vitamin D supplementation of preschoolers makes even a small contribution to improving these common childhood health problems, measures to increase vitamin D levels may significantly reduce population wide morbidity and associated health service costs.
TARGet Kids! infrastructure and collaborations make this team unique in Canada and position it ideally to carry out this randomized controlled trial on vitamin D supplementation of Canadian preschoolers. The recommended vitamin D dietary allowance (RDA) for children older than 1 year has been set at 600 IU/day by both Health Canada and the Institute of Medicine. Because children who consume less than 1000 ml of vitamin D fortified cow's milk per day (which includes most preschoolers) [2, 25] are unlikely to receive this amount of dietary vitamin D, the AAP recommends routine vitamin D supplementation of 400 IU/day for all children ingesting < 1000 ml/day of vitamin D-fortified formula or cow's milk. [3] The CPS has no recommendation for routine vitamin D supplementation for Canadian children older than 1 year. [4] To reflect current AAP recommendation and standard practice in our population, our 'standard dose' arm has been chosen as 400 IU/day.
SECTION 2: OBJECTIVES AND HYPOTHESIS
D. Low vitamin D levels in North American children:
There is consistent evidence, from both single center studies [14, 28, 29] and national surveys [15, 16, 25] , that North American children older than 1 year have vitamin D serum levels lower than AAP or CPS recommendations (See Table 1 
Viral Upper Respiratory Tract Infection
Viral upper respiratory tract infections (URTI) are the most common infectious disease in North America. [40] URTI is the most common reason for emergency department visits and unscheduled outpatient visits in Canada comprising 10% of emergency department visits for children under 10 years of age. [5, 41, 42] Preschoolers have the highest incidence of URTI of any age group, occurring one to two times per month per child during the winter and higher among children who attend daycare. [40, [43] [44] [45] [46] [47] [48] [49] [50] [51] Influenza, RSV and adenovirus, which collectively comprise 25% of respiratory infections in children, are the most common viruses that lead to febrile illness, acute otitis media, outpatient visits and hospitalization. [43, 52, 53] Roughly 50% of preschoolers with URTI are brought to medical attention resulting in an additional outpatient physician visit every 2 to 3 months during the winter with 1% requiring hospitalization. [43, 52, [54] [55] [56] Several groups have estimated the direct and indirect costs of URTI in preschoolers to be between $261 and $276 per URTI with influenza being the most costly virus, contributing $809 per URTI. [45, 54] The collective cost of URTI in children under 5 years of age has been estimated to be $1.8 billion annually in the US. [57] Evidence supporting a causal connection between low vitamin D serum level and URTI comes from multiple sources.
Temporality: Both vitamin D levels and viral URTI show a remarkably similar seasonal oscillation. R. Edgar Hope-Simpson hypothesized that a "seasonal stimulus" must affect the pathogenesis of influenza and Cannel et al. hypothesized that this seasonal stimulus may be related to seasonal oscillation of vitamin D levels. [58, 59] Biological plausibility: Basic science has uncovered the role of vitamin D on the innate immune system. [60] The primary site for human contact with respiratory viruses is the upper respiratory tract mucosa. [61] It has been shown that vitamin D is constitutively converted to its active form 1,25-hydroxyvitamin D in respiratory epithelium. [62] The mucosa of the upper airway is protected from infection by a complex set of peptides which have direct antimicrobial properties and contribute to innate immunity. [63, 64] These peptides include defensins and calethicidin which have direct antiviral properties. [65] [66] [67] 
Asthma
Asthma is the most common chronic illness of childhood. Preschoolers bear the highest burden of asthma which affects 13% of children under 5 years of age compared with 8% of children under 18 years in Ontario. [83] Asthma exacerbations are the most common non-surgical cause for hospitalization of children in Canada and it costs the Canadian health care system over $300 million annually. [83] [84] [85] [86] An association between vitamin D deficiency and asthma exacerbation was initially proposed to explain the observation that low vitamin D levels and asthma exacerbations are both more common in temperate climates and more common during the winter months. [87, 88] Recent basic science and epidemiological research has supported a connection between vitamin D serum level and asthma.
Biological plausibility:
In vitro studies have demonstrated that the VDR is present in bronchial smooth muscle cells and that many asthma-associated genes are expressed following stimulation of lung tissue with vitamin D. [89, 90] Case-control studies have found associations between asthmatic individuals and polymorphisms in the VDR and other vitamin D related genes. [91] [92] [93] [94] [95] Epidemiologic Association: Cross-sectional data from NHANESIII found a strong correlation between airway resistance and vitamin D levels in adults. [96] An examination of incident vitamin D levels in a cohort of 1024 seven to ten year old American children with mild-to-moderate asthma identified that 
Randomized controlled trial (RCT) evidence:
To our knowledge, no RCT has examined the effect of vitamin D on preschool asthma exacerbations. In the trial by Urashima and colleagues of vitamin D supplementation of Japanese schoolchildren, asthma exacerbations were measured as a secondary outcome. [80] They found a statistically significant decrease in asthma exacerbations in children receiving 1200 IU of vitamin D per day vs. placebo (2 vs. 12 of 167 children, RR 0.17, p=0.006). Interestingly, the reduction in URTI was stronger among children with asthma than those without (RR 0.17, p=0.006) suggesting that the reduction in exacerbations of asthma may be mediated through reduced viral URTIs among vitamin D supplemented children.
F. Summary of Background
There is substantial evidence that many North American preschoolers have vitamin D serum levels significantly lower than both Canadian and American guidelines suggest. However, these guidelines are not based on child health outcome data but on expert opinion and extrapolation from adult outcomes. 
SECTION 4: METHODS A. Study design
A multi-centre, pragmatic, active controlled, blinded, parallel group, superiority randomized trial will be conducted over two winters. The primary purpose of this trial is to inform health policy and secondarily to contribute to an explanation of the causal relationship between vitamin D and child health outcomes. Therefore, according to the framework described by Thorpe (co-investigator) and other leading trial methodologists, this trial has been designed along the pragmatic end of the pragmatic-explanatory continuum. [102] Specifically, eligibility criteria, participant compliance, follow-up intensity, and primary analysis will follow pragmatic approaches ("Does this intervention work under usual conditions?"); follow-up of outcomes will follow approaches mid-way along the pragmatic-explanatory continuum ("Can this intervention work under ideal conditions?"). This protocol has been designed following the 2010 SPIRIT guidelines (Defining Standard Protocol Items for Randomized Trials). [103, 104] and trial results will be reported according to the 2008 CONSORT guidelines for pragmatic trials. [105] B. Participants
Study Setting
Healthy children aged 1 to 5 years will be recruited during a routine well child doctor's visit at a TARGet Kids! participating academic pediatric or family medicine group practice in Toronto, Canada Enrolled in TARGet Kids! Exclusion criteria are 1) Children with gestational age < 32 weeks as they are a high risk population for respiratory tract infection and asthma; 2) Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection; 4) Children with a sibling participating in the study to reduce clustering effects
Baseline Descriptor Variables
Baseline descriptor variables will be obtained by standardized research assistant completed data collection form adapted from the Canadian Community Health Survey. [106] The following will be collected: Age, sex, birth weight, enrolment date, ethnicity, maternal age, education and health, duration of breastfeeding, current and past vitamin D supplementation, dietary vitamin D intake using 3 day dietary recall, bottle use, daily multivitamin use, influenza immunization status, screen viewing time, physical activity, outdoor time, and sun exposure. In addition, height and weight will be measured using standardized techniques and skin pigmentation will be measured using a narrow-band reflectometer (Dermaspectrometer, Cortex Technology). [107] [108] [109] [110] This data was be collected as part of "TARGet Kids!", and will be linked to this study. This is to avoid the inconvenience and redundancy of asking parents to complete the questionnaires twice and complete the height and weight measurements twice. A venous blood sample will be obtained to document baseline 25-hydroxyvitamin D levels.
C. Intervention
Children will be randomly assigned to one of two groups: 'standard dose' of 400 IU/day vitamin D or Parents of children in each group will be instructed to administer 1 drop of the provided solution to their child by mouth once daily, at any time of day, each day from the time of enrolment (September-November) over the winter until seen in follow-up (April-May) 4-8 months later. The duration of the intervention (4-8 months) has been chosen to mimic the routine practice of vitamin D supplementation of preschoolers over the Canadian winter. A drop based formulation has been chosen to facilitate ease of administration to young children. Vitamin D3 containing solutions will be provided in kind by Ddrops TM . Actual vitamin D concentrations provided to study participants will be verified using established analytical techniques on a subset of provided solutions. [111, 112] Concomitant interventions prohibited include over the counter multivitamins which contain vitamin D, over the counter vitamin D preparations and prescription vitamin D. As this is a pragmatic trial, no specific strategies will be introduced to improve adherence. To monitor adherence at the end of the trial, parents will be asked to return bottles and the amount of vitamin D administered will be calculated based on the volume of solution remaining. No specific criteria will be developed for discontinuation or modification of the interventions, as the doses of vitamin D are within the safe and recommended dosages for children. [81] 
D. Randomization
Stratification, Blocking and Sequence Generation
Children will be randomized to 'standard dose' or 'high dose' groups. Block randomization will occur by study site with blocks of varying sizes. [103] Block randomization ensures that group sizes are similar at the end of each block. This is particularly important in a study of vitamin D and URTI, as date of enrolment (time) may be an important covariate. Sequence generation stratified by clinic site will be performed by the Pharmacy Department at The Hospital for Sick Children using a computer random number generator.
Allocation Concealment Mechanism
Allocation concealment is the process that prevents any trial participant or investigator from knowing the treatment to which subjects will be assigned, and prevents selection bias. Allocation concealment will be achieved by having the Pharmacy Department prepare the vitamin D preparations in sealed, serially numbered bottles identical in appearance and weight.
Implementation
The Research Pharmacist will generate the allocation sequence; Research Assistants at each clinic site will enrol and assign participants to the interventions.
E. Duration of treatment
As 25-hydroxyvitamin D levels are reported to stabilize within 8 weeks, [113, 114] and respiratory viruses tend to circulate in Canada November through April, [115] children will be recruited September through November and parents will be asked to provide the daily study supplement from the time of enrolment through the winter until seen in follow-up 4 to 8 months later in April or May.
F. Outcomes
Primary Outcome
The primary outcome will be the number of laboratory-confirmed viral URTIs per child over the winter months. Because of the wide variety of respiratory viruses and URTI illness presentations, signs and symptoms of viral URTI are non-specific and may not be reliably measured by parental report. [116, 117] Secondary Outcomes Secondary outcomes include parent reported URTI, viral agent (specifically influenza, adenovirus and RSV which are the most likely viruses to cause illness), wheezing episodes among children with asthma, physician-diagnosed otitis media and pneumonia. Direct health services related costs as well as indirect costs to families from URTI will be calculated using an economic analysis described below. Follow-up 25-hydroxyvitamin D level will be measured in order to determine the vitamin D dose vs. serum response relationship. Finally, change in 25-hydroxyvitamin D level from baseline will be determined to document that an improvement in health outcomes is mediated through an increase in 25-hydroxyvitamin D serum level.
G. Outcome measurement
Viral isolation
Parents of enrolled children will be asked to obtain a nasal swab from their child and complete a symptom checklist with each URTI. Parental obtained nasal swabs have been shown to be as effective in detecting respiratory viruses as health professional obtained nasopharyngeal sampling but less invasive and better tolerated. [118] Parents will be instructed to place the swab in provided viral transport media and refrigerate until couriered to the study laboratory within 24 hours. [43, 119] Reverse transcriptase polymerase chain reaction (RT-PCR) will be performed on each sample which has a sensitivity of 95% and specificity of 100% for the identification of respiratory RNA viruses which is more sensitive than viral culture and comparable to immunofluorescence. [120, 121] Samples will be tested for 18 common respiratory viruses including influenza A and B, adenoviruses, respiratory syncytial virus (RSV), picornaviruses (enteroviruses and rhinoviruses), coronovirus, metapneumovirus and parainfluenza virus using the ID-Tag TM RVP assay using the Luminex xMAP TM system (Cat# R019A0105, TM Bioscience Corp., Toronto, ON). [122] [123] [124] This is the same assay and machine that is routinely used in the Ontario public health laboratories.
Parent reported URTI
Parental reported URTI symptoms will be defined as two or more of fever (>38°C), cough, runny nose, sore throat, headache, vomiting, feels unwell, muscle aches, ear ache or infection, poor appetite, not sleeping well, cranky/fussy, low energy or crying more than usual from a validated parent completed symptom checklist (CARIFS) collected with the viral sample. CARIFS has been developed, validated and extensively used by our team and others.[125-127] A new URTI cannot commence until ≥ 3 symptom free days since the end of a previous URTI. [43] Asthma exacerbation Asthma will be defined as parental report of asthma plus confirmation from the child's medical record of 2 or more episodes of wheeze requiring the prescription of inhaled asthma controlling medications.[128, 129] Asthma exacerbation will be defined as a wheezing episode in children with asthma as obtained from parent completed symptom checklist based on the International Study of Asthma and Allergies in Childhood (ISAAC).
[129]
Serum vitamin D level
Blood for serum levels will be drawn by trained pediatric phlebotomists from the antecubital vein for determination of 25-hydroxyvitamin D. Specimens will be sent to the Clinical Biochemistry Laboratory at the Mount Sinai Hospital with the study requisition, where they will be processed according to standard procedures. Under the direction of Dr. Reinhold Vieth who is an internationally recognized expert in vitamin D biochemistry and director of the Bone and Mineral Laboratory at Mount Sinai Hospital, total 25-hydroxyvitamin D will be measured from serum samples using a competitive two-step chemiluminescence assay which has been validated for measurement of 25-hydroxyvitamin D in children older than 1 year of age. [130, 131] The specific instrument that will analyze all samples is a Diasorin LIAISON® 25-hydroxyvitamin D TOTAL.
[132] This technique and instrument have been chosen to be consistent with national vitamin D surveys from both Canada and the United states. [16, 25] Extensive testing and validation of this machine has been performed and has demonstrated an intraassay imprecision of 7.2% at a concentration of 213 nmol/L and an interassay imprecision of 4.9% at 32 nmol/L, 8.9% at 77 nmol/L and 17.4% at 213 nmol/L, values which are well within acceptable limits for biochemical measurements. During this study, the instrument will be monitored using the UK DEQUAS external quality assessment scheme which is an internationally recognized vitamin D quality assessment protocol. [133] Other outcome measures Physician-diagnosed otitis media, pneumonia, emergency department visits and hospitalizations will be collected by monthly telephone call and confirmed by review of the child's clinic medical record.
H. Duration and frequency of follow-up
Parents will receive a monthly telephone call by a research assistant reminding them to collect nasal samples and complete symptom checklists. This methodology has been used successfully by our group and others. [43, 45, 119, 126] In addition, parents will be asked to return to their child's physician's office in April or May for measurement of 25-hydroxyvitamin D level by blood test and the completion of a post-intervention survey. I. Co-interventions The following potential co-interventions will also be measured at the follow-up visit: Influenza vaccination, dietary vitamin D intake measured by research assistants using a 3 day dietary recall, [106] over the counter vitamin and mineral supplementation (ie. calcium containing multivitamins), herbal remedies (ie. echinacea) and hours per week in daycare. J. Blinding Parents, attending physicians, laboratory personnel, and study personnel conducting the outcome assessments, data analysts and investigators will be blind to the group allocation. Study medication will be supplied in bottles that look identical, and the appearance, consistency and taste of the drops will be similar. Group allocation will be concealed until the final data analysis is performed. K. Target sample size The sample size was based on asymptotic methods for a likelihood ratio test assuming a Poisson distributed outcome and was confirmed by simulation studies. All sample size and power calculations assume a 5% Type I error probability (two-sided). If we assume an average of one URTI per month during the winter months [40, [43] [44] [45] [46] [47] [48] [49] [50] [51] among children receiving the standard dose of vitamin D, we would therefore expect an average of four URTI per child over the winter. A sample size of 300 per group would give 90% power to detect a reduction in the average number of URTI per winter of one URTI. This sample size will retain sufficient power if the seasonal incidence of URTI is lower. Similarly, larger differences will be detected with power exceeding 90%. We believe that, even one fewer URTI over the winter would be a clinically important outcome, especially to families with young children. Although the study is not powered to detect reductions of specific kinds of infections, a conservative estimate is that at least 25% of children will have one of RSV, Adenovirus or Flu which collectively result in the greatest burden of illness in this population, [43, 52, 53] this sample size gives 80% power to detect a 50% absolute reduction in this composite outcome.
Preliminary TARGet Kids! data has suggested an 80% retention rate [134, 135] therefore, to accommodate a 20% loss to follow-up, 375 children will be recruited to each group (750 total).
L. Feasibility
Since September 2008, over 3500 children age 1-5 years have been recruited through TARGet Kids! practices with collection of non-invasive measures including completion of questionnaires (demographics, SES, family/lifestyle factors) and anthropometric measures (height, weight and waist circumference). Since February 2009 venous blood samples have been collected from over 1500 children.
[134] TARGet Kids! is now operating out of six sites with over 100 children per month being recruited with phlebotomy. Therefore, recruitment of 200 children over three months (SeptemberNovember) in 4 separate years for this study will be feasible. M. Statistical analysis Baseline characteristics will be summarized by appropriate descriptive statistics. Although randomization is expected to balance the covariates, variables that demonstrate, by chance, a potentially clinically meaningful imbalance, will be considered as possible adjusting covariates.
All outcomes will be analyzed following the intention-to-treat principle.
[136] The primary analysis of the primary outcome will assess the effect of vitamin D supplementation on laboratoryconfirmed URTI. Mean (per child) URTI rates will be computed for each group. A Poisson regression model will be used to make the statistical comparison between the groups. Variable length of followup time will be accounted for by using a suitable offset (logarithm of observation duration) in the Poisson model. If there is evidence of overdispersion, a negative-binomial model may be considered. The secondary analysis of the primary outcome will use survival methods to examine time to first URTI and the Andersen-Gill extension of the Cox model will be used to analyze recurrent URTI events.
[137] The rationale for conducting the trial over 4 seasons is to increase the chance of a sufficiently active viral season to assess a protective effect of the intervention. This will also allow us to examine the consistency of the effect over the 4 seasons as strains of viruses vary from year to year.
Analysis of secondary outcomes will use standard methods for continuous data (ie. vitamin D level) using means, ANOVA and linear regression with and without adjustment for baseline group differences. The incidence of binomial secondary outcomes such as specific viral infections will be summarized descriptively. Since the incidence of some infections may be low, logistic regression analyses will only be performed to statistically assess the treatment effect when there are sufficient events (between 30 and 60). Subgroup analyses will be conducted for children with asthma. Frequency of asthma exacerbations will be analyzed similarly to the primary outcome.
N. Economic Analysis
Cost-consequence and cost-effectiveness analyses will be conducted using data from this clinical trial. A societal perspective will be employed as both direct health service utilization costs as well as indirect costs to families from URTI will be calculated for the 'high dose' vs. 'standard dose' groups. The time horizon of the analysis will be limited to the follow-up of this trial in order to leverage direct data. Given the short time horizon of this analysis, discounting of costs and outcomes will not be applied. This analysis will include the cost of 'high dose' vitamin D supplementation, physician visits, medications (antimicrobial and over the counter), hospital admissions, emergency department visits and laboratory testing abstracted from the child's medical record and costs associated with lost income from parental work absenteeism and time out of daycare obtained by monthly telephone call using previously described techniques. [45, 55, 86, 126 , 138] Standard, publicly available costing sources will be used to cost resource utilization parameters. Specifically, we will use cost sources such as the Ontario Health Insurance Programs (OHIP), Ontario Case Costing Initiative (OCCI) and standard Ministry of Health (MOH) reimbursements for diagnostic tests. Sex-weighted hourly wage rate will be derived from Statistics Canada Data. For the cost-effectiveness analysis, the cost-effectiveness parameters will be the cost per laboratory-confirmed URTI avoided. The net benefit regression approach will be used to determine each patient's net benefit from treatment (NB i ) based upon the data collected on resource use and lost parental productivity. [139, 140] Graphs will be used to illustrate the incremental net benefit assuming varying willingness to pay. Each estimate of net benefit can be adjusted for potential confounders through regression. In its simplest form, net benefit regression involves fitting the following simple linear regression model: NB i = 0 + TX TX i + i where TX i is the i th person's treatment indicator (TX i = 1 for new treatment and 0 for usual care) and i is a stochastic error term. [141] Confidence intervals for incremental net benefit will be compared to results of non-parametric bootstrapping to characterize statistical uncertainty in the economic analysis. O. Compliance Parents of participating children will receive a monthly telephone call reminding them to administer the study supplement daily and recording the number of missed days. In addition, compliance with supplementation will be measured by volume of solution left in vitamin D bottles at follow-up. [142] P. Recruitment and retention Strategies to achieve adequate recruitment will include approaching eligible subjects during a well child visit. Lists of children scheduled for a well child visit will be reviewed in advance; letters inviting participation will be mailed 2 to 4 weeks in advance of the visit. Subjects will be approached in person by the research assistant while registering for the clinic visit. At the initial visit, non-invasive measures (questionnaires, anthropometric measures) will be collected while the child and family are waiting for their appointment with baseline blood sampling occurring after the appointment. These methods have been successfully used in other TARGet Kids! studies. [2, 26, 27, 134, 143, 144] Strategies for retention include a monthly telephone call to encourage collection of nasal swabs and completion of symptom checklists. Every reasonable attempt will be made to locate patients at follow-up. Topical anesthetic cream (EMLA or Ametop) will be offered to minimize discomfort from venipuncture. Blood will be drawn in the primary care physician's office negating the need to attend a Version April 24, 2011 13 separate laboratory visit. Parents who have moved out of district will be offered to visit the Hospital for Sick Children for repeat laboratory testing. Furthermore, for children who do not attend their follow-up visit and refuse to visit the Hospital for Sick Children, a home visit for phlebotomy will be offered. This is expected to occur in less than 10% of subjects. Q. Participant timeline: Participants will be recruited September through November with baseline survey data, anthropometrics and baseline vitamin D serum level collected and followed until seen in follow-up in April or May to capture peak respiratory virus season. At the follow-up visit blood will be drawn for 25-hydroxyvitamin D level and a post intervention survey completed. This will occur over four seasons with different participants recruited in each season as respiratory virus incidence, distribution and severity tend to vary from year to year.)
SECTION 5: DATA COLLECTION AND MANAGEMENT A. Data collection methods
Plans for the collection of baseline data and outcome assessment are described in Section 4B (Participants), 4F (Outcomes) and Section 4Q (Timeline). To ensure high quality data collection, research assistants will be trained in the accurate completion of questionnaires, anthropometric measurement and will be registered pediatric phlebotomists as per standard TARGet Kids! operating protocol. Weight will be measured using a precision digital scale (±0.025% SECA, Hamburg Germany) and standing height will be measured using a stadiometer (SECA, Hamburg Germany). Michael's Hospital will be the data coordinating centre for this study. AHRC is a not-for profit academic research organization, dedicated to serving the needs of clinical investigators by providing the best research solutions. Medidata RAVE by Medidata Solutions Inc. is the electronic data capture technology and data repository for TARGet Kids! data collected during this study. Medidata RAVE is an industry-leading electronic data capture and clinical data management system, with user-configurable workflows, sophisticated case report form (CRF) design, complex edit checking, and customized security parameters. Medidata RAVE allows TARGet Kids! research assistants to enter data in real time to the TARGet Kids! central database from any of the practice sites. Medidata RAVE has extensive built-in reporting capabilities, and data can be exported to standard formats for data analysis (SAS, SPSS, and others). Laboratory tests from Mount Sinai Services will be directly uploaded to Medidata RAVE through a secure web portal. These features enable TARGet Kids! to be highly efficient and are vital to the success of this project.
SECTION 6: ETHICAL CONSIDERATIONS AND SAFETY A. Ethics
An information package will be mailed to each family 2 to 4 weeks prior to being formally recruited. This will allow parents time for consideration in advance and reduce pressure to participate. Parents will benefit by the provision of 4-8 months of vitamin D supplementation for their child free of charge. Children may directly benefit via the identification of viral etiology for URTI symptoms and through identification of vitamin D deficiency. The child's pediatrician will receive viral test results as well as blood results and manage according to national clinical guidelines. [4] Parents of all study participants will have provided informed consent. The investigators will seek approval from the Hospital for Sick Children Research Ethics Board.
While a placebo arm may be ethically justified given the lack of evidence supporting improved health outcomes with supplementation, it is unlikely to be feasible given that current AAP vitamin D guidelines (2007) include a recommendation for routine vitamin D supplementation for children older than 1 year and the majority of families in our population are following this recommendation. [3, 27] B. Safety As vitamin D dosages in this study are within the Tolerable Upper Intake Level as recommended by Health Canada for children older than 1 year of age (2500 IU per day for children 1-3 years and 3000 IU/day for children 4-8 years), risk of vitamin D excess is low. [145] In addition, other studies which have used vitamin D doses of up to 50,000 IU per week in children did not show evidence of vitamin D toxicity. [146, 147] However, we will monitor for adverse events among study participants by having collaborating community physicians aware of signs and symptoms of vitamin D toxicity including nephrolithiasis and hypercalcemia. All adverse events will be reported to the Hospital for Sick Children's and St. Michael's Hospital's Research Ethics Board according to institutional adverse event reporting requirements. All serious, unexpected adverse drug reactions to the study medication will be reported to Health Canada within 15 calendar days or for death or life-threatening events, within 7 calendar days. In the latter case, a follow-up report will be filed within 8 calendar days. Additionally, each participant will be assessed for signs of vitamin D toxicity at follow-up through measurement of serum calcium, alkaline phosphatase and parathyroid hormone.[23, 148, 149] A Data Safety and Monitoring Board (DSMB) will be established. The DSMB will be responsible for oversight of data and safety. The DSMB will be composed of experts in pediatric medicine, endocrinology, infectious disease and biostatistics and clinical trial methodology. The DSMB members will be independent of all those participating in the study. The DSMB will review data on adverse events, data quality, trial efficacy and subject recruitment between years 1 and 2. The DSMB will prepare meeting minutes and make recommendations about study conduct to the Principal Investigator.
SECTION 7: KNOWLEDGE TRANSLATION
TARGet Kids! is a unique collaboration between child health researchers at the St. Michael's Hospital, The Hospital for Sick Children and community health care providers. It provides a novel opportunity for truly integrated knowledge translation. TARGet Kids! primary care physician members have participated in the early stages of shaping the research process to reach the overarching TARGet Kids! goal: to promote health for all Canadian children. Other members of TARGet Kids! include policy makers in primary care.
Findings from this research will be disseminated directly to the physician participants and to their patients. A meeting of all the TARGet Kids! practices (physicians, nurses, office staff), research team (investigators, research assistants, students), and policy leaders (representatives from Section of Community Paediatrics, Family and Community Practice, Ontario Medical Association, and parent representatives) occurs annually. Downstream dissemination to primary care physicians will occur through formal and informal venues at local levels, such as City Wide Paediatric Rounds, HSC Paediatric Update and those held by local physician groups.
End of grant knowledge will be shared with the academic community through publication in relevant journals and presentations at national and international conferences, and locally through hospital rounds and presentations. Messages will be relevant to professionals working in the fields of Version April 24, 2011 15 pediatrics, family medicine, endocrinology, infectious disease, nursing, dietetics, and public health. Information will be disseminated to professionals by the research team with colleagues at the Ontario Agency for Health Protection and Promotion, the Centre for Effective Practice, the Maternal Infant Child and Youth Research Network (MICYRN), the Ontario Medical Association, the Canadian Pediatrics Society and the American Academy of Pediatrics. Opportunities for coverage in lay media will be sought using an experienced knowledge broker (funded by current grants).
SECTION 10: SUMMARY
There is compelling evidence that young children in North America have vitamin D levels significantly lower than experts recommend. Basic science and epidemiological studies make the case that low wintertime vitamin D levels may be related to two common and costly child health outcomes: wintertime viral URTI and asthma exacerbations. This study will be the first RCT to investigate vitamin D related health outcomes in preschoolers. The results of this trial will make an immediate contribution by defining clinical practice standards for vitamin D supplementation for young children and provide an evidence base for national vitamin D guidelines.
Key strengths of this proposal are a novel and important research question, the outcome of which could affect nearly every young child in Canada, a methodologically rigorous plan and an implementation strategy that leverages the efficiency of the only primary care research platform for children in Canada: TARGet Kids!. Furthermore, the investigators form a solid team of highly qualified methodologists, content experts and primary care providers who have come together with the aim of integrated knowledge translation between policy makers, investigators, physicians and families.
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Northstone Stoian [17] Toronto, Canada For each site in the forest plot, a box represents the incidence rate ratio and a horizontal bar represents 95% confidence intervals. 5 out of 8 sites are represented in the plot; the remaining 3 sites had too few participants to calculate incidence rate ratios (nsite6=4, nsite7=17, nsite8=16). The overall incidence rate ratio is plotted as a diamond, with the lateral points indicating the 95% confidence interval. 
